|Day Low/High||26.87 / 27.37|
|52 Wk Low/High||6.39 / 30.45|
Charts and indicators for the homebuilder are constructive.
These companies are trading at reasonable multiples and two are offering nice dividend yields, too.
I feel good in recommending the long side of LEN at current levels.
Furniture sellers, homebuilders and home improvement and décor retailers should benefit as people establish new digs outside urban areas.
Some stocks have rebounded far more than expected while others appear to be getting back into gear.
Here's how to trade shares of the nation's fifth largest homebuilder.
After the strong run of homebuilders in 2019, the sector simply isn't as oversold as it was to start the year.
Low interest rates, continued low unemployment and high consumer confidence are bullish props to this sector.
The two are homebuilding and biotech, and there are stocks within those sectors where I've parked my money.
Beazer Homes USA, Taylor Morrison Home Corp. and Hooker Furniture is a trio to consider.
They're the kind of names, along with a big dollop of cash in my portfolio, I plan to wait out the 'trade wars'.
The housing market should post much stronger performance in the second half of the year, provided the jobs market remains solid. Here's how to play it.
I do think consolidation across this very fragmented industry will pick up in the quarters ahead.
Achaogen, Taylor Morrison and Synchrony Financial are a part of my current shopping list.
Legislation should provide a powerful earnings boost for the industry and these names.
The market continues to be slightly positive in a day that has seen little movement in the major indices since the open. It seems housing is becoming a battleground sector among analysts lately. Barclays downgraded myriad homebuilders after recent r...
Smaller builders are of particular interest because they're acquisition candidates in a fragmented market.
The two sectors hold more promise than most in the back half of 2017.
It is hard to keep up with the flurry of first-quarter earnings reports hitting the wires this morning. Here are a few that caught my eye today. Biotech stalwarts Amgen and Celgene posted mixed results, while AbbVie seems to have beat both top- and ...
They have faster growth prospects and sell for slightly cheaper valuations, as well.
Home builders make up the second-largest allocation in my portfolio, behind biotech.
This is a great shopping list of undervalued stocks with the potential for big long-term returns.